{"id":"atv-r","safety":{"commonSideEffects":[{"rate":"35–49","effect":"Hyperbilirubinemia"},{"rate":"8–14","effect":"Nausea"},{"rate":"6–16","effect":"Diarrhea"},{"rate":"4–7","effect":"Headache"},{"rate":"2–4","effect":"Rash"},{"rate":"2–4","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL1163","moleculeType":"Small molecule","molecularWeight":"704.87"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atazanavir (ATV) is an HIV protease inhibitor that binds to and inhibits the HIV protease enzyme, which is essential for processing viral proteins and producing mature, infectious viral particles. Ritonavir (r) is a potent CYP3A4 inhibitor used as a pharmacokinetic booster to increase atazanavir plasma concentrations and half-life, allowing for lower doses and improved dosing convenience. Together, ATV/r suppresses HIV replication and reduces viral load in infected individuals.","oneSentence":"ATV/r is a protease inhibitor boosted with ritonavir that blocks HIV protease, preventing viral replication by inhibiting the cleavage of viral polyproteins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:26:24.543Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced adults"},{"name":"HIV-1 infection in combination antiretroviral therapy"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT02284035","phase":"PHASE3","title":"Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2015-09-27","conditions":"AIDS","enrollment":75},{"nctId":"NCT04466241","phase":"PHASE2, PHASE3","title":"Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2020-11-27","conditions":"COVID-19, COVID-19 Drug Treatment, Severe Acute Respiratory Syndrome Coronavirus 2","enrollment":294},{"nctId":"NCT04121195","phase":"PHASE2, PHASE3","title":"Dose Escalation Study to Determine the Pharmacokinetics of Atazanavir Administered With RIfampicin to HIV Positive Adults on sEcond-line ART Regimen With Suppressed HIV-1 Viral Load","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2020-10-30","conditions":"HIV/AIDS, Tuberculosis","enrollment":26},{"nctId":"NCT01511809","phase":"PHASE3","title":"Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2010-09","conditions":"HIV-1 Infection","enrollment":117},{"nctId":"NCT04022967","phase":"PHASE3","title":"ANRS 12372 MODERATO Study","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2020-09-21","conditions":"HIV-1-infection","enrollment":480},{"nctId":"NCT02194998","phase":"PHASE2","title":"Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-09-16","conditions":"HIV Infections, Hepatitis C","enrollment":46},{"nctId":"NCT04385719","phase":"PHASE2","title":"Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral Therapy","status":"COMPLETED","sponsor":"Makerere University","startDate":"2021-05-05","conditions":"Ebola, HIV/AIDS","enrollment":24},{"nctId":"NCT03708861","phase":"PHASE3","title":"Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients","status":"WITHDRAWN","sponsor":"University of Turin, Italy","startDate":"2016-01","conditions":"HIV Infection","enrollment":""},{"nctId":"NCT04311957","phase":"PHASE4","title":"Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults","status":"UNKNOWN","sponsor":"Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic","startDate":"2020-09-01","conditions":"HIV-1-infection, Antiretroviral Therapy","enrollment":386},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT00411957","phase":"PHASE1, PHASE2","title":"Pharmacokinetic Study of 2 Doses of ATV/r OD + 2 NRTIs in Thai HIV-1 Infected Patients","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2007-01","conditions":"HIV Infections","enrollment":22},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT00335322","phase":"PHASE4","title":"ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2007-02","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":329},{"nctId":"NCT02155101","phase":"PHASE3","title":"Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2014-05","conditions":"HIV/AIDS","enrollment":120},{"nctId":"NCT02116660","phase":"PHASE2","title":"Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-09-03","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT01641367","phase":"PHASE4","title":"A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-02-22","conditions":"HIV-1 Infection","enrollment":545},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT02386098","phase":"PHASE2","title":"Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults","status":"TERMINATED","sponsor":"ViiV Healthcare","startDate":"2015-07-08","conditions":"HIV Infections","enrollment":86},{"nctId":"NCT01903031","phase":"PHASE2","title":"Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2014-12-30","conditions":"HIV-1 Infection","enrollment":84},{"nctId":"NCT00756730","phase":"PHASE4","title":"Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r","status":"COMPLETED","sponsor":"Community Research Initiative of New England","startDate":"2008-09","conditions":"HIV Infections","enrollment":49},{"nctId":"NCT00491556","phase":"NA","title":"Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r)","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2007-10","conditions":"HIV Infections","enrollment":102},{"nctId":"NCT01829802","phase":"PHASE4","title":"RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients","status":"UNKNOWN","sponsor":"Pedro Cahn","startDate":"2014-05","conditions":"Chronic Infection With HIV","enrollment":50},{"nctId":"NCT01159223","phase":"PHASE4","title":"Low Dose Atazanavir/r Versus Standard Dose Atazanavir/r (LASA)","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2011-05","conditions":"HIV Infections","enrollment":559},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT00445146","phase":"PHASE2","title":"Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2007-02","conditions":"HIV Infections","enrollment":192},{"nctId":"NCT00892437","phase":"PHASE2","title":"Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2009-05","conditions":"HIV-1 Infection","enrollment":85},{"nctId":"NCT00814879","phase":"NA","title":"Pilot Study of a Raltegravir Based NRTI Sparing Regimen","status":"COMPLETED","sponsor":"Yale University","startDate":"2009-05","conditions":"Acquired Immune Deficiency Syndrome, AIDS, Human Immunodeficiency Virus","enrollment":60},{"nctId":"NCT00851799","phase":"","title":"Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-06","conditions":"HIV Infection","enrollment":334},{"nctId":"NCT01106586","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-04","conditions":"HIV, HIV Infections","enrollment":708},{"nctId":"NCT00977756","phase":"","title":"IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2002-08","conditions":"HIV Infections","enrollment":168},{"nctId":"NCT01307488","phase":"PHASE4","title":"Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2011-09","conditions":"HIV Infection","enrollment":286},{"nctId":"NCT01467479","phase":"PHASE3","title":"A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2011-12","conditions":"Hepatitis C","enrollment":185},{"nctId":"NCT01180075","phase":"","title":"Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2010-05","conditions":"Human Immunodeficiency Virus","enrollment":85},{"nctId":"NCT02245269","phase":"PHASE1","title":"Pharmacokinetics of Atorvastatin With Tipranavir/Ritonavir and the Effect of Antacid on the Pharmacokinetics of Single-Dose Tipranavir/Ritonavir in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-07","conditions":"Healthy","enrollment":23},{"nctId":"NCT01656109","phase":"PHASE2","title":"Atazavanir/Ritonavir-based HAART in Children","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2011-07","conditions":"HIV","enrollment":20},{"nctId":"NCT00552240","phase":"PHASE4","title":"Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-09","conditions":"HIV Infections","enrollment":154},{"nctId":"NCT00884793","phase":"NA","title":"Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-09","conditions":"HIV Infections","enrollment":8},{"nctId":"NCT00440947","phase":"PHASE3","title":"Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2007-03","conditions":"Infection, Human Immunodeficiency Virus I, HIV Infection","enrollment":515},{"nctId":"NCT00120393","phase":"PHASE3","title":"Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-01","conditions":"HIV Infections","enrollment":192}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":254,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Atazanavir/Ritonavir","Atazanavir/r"],"phase":"marketed","status":"active","brandName":"ATV/r","genericName":"ATV/r","companyName":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","companyId":"advancing-clinical-therapeutics-globally-for-hiv-aids-and-other-infections","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ATV/r is a protease inhibitor boosted with ritonavir that blocks HIV protease, preventing viral replication by inhibiting the cleavage of viral polyproteins. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in combination antiretroviral therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}